Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F13%3A10209664" target="_blank" >RIV/00216208:11130/13:10209664 - isvavai.cz</a>
Alternative codes found
RIV/62156489:43210/13:00212804 RIV/00216305:26620/13:PU95529 RIV/00064203:_____/13:10209664
Result on the web
<a href="http://www.ncbi.nlm.nih.gov/pubmed/23687925" target="_blank" >http://www.ncbi.nlm.nih.gov/pubmed/23687925</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine
Original language description
This review provides a brief overview of the variety of carriers employed for targeted drug delivery used in cancer therapy and summarizes advantages and disadvantages of each approach. Particularly, the attention was paid to polymeric nanocarriers, liposomes, micelles, polyethylene glycol, poly(lactic-co-glycolic acid), dendrimers, gold and magnetic nanoparticles, quantum dots, silica nanoparticles, and carbon nanotubes. Further, this paper briefly focuses on several anticancer agents (paclitaxel, docetaxel, camptothecin, doxorubicin, daunorubicin, cisplatin, curcumin, and geldanamycin) and on the influence of their combination with nanoparticulate transporters to their properties such as cytotoxicity, short life time and/or solubility.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
CE - Biochemistry
OECD FORD branch
—

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)